See more : Kemper Corporation 5.875% Fixed (KMPB) Income Statement Analysis – Financial Results
Complete financial analysis of Milestone Scientific Inc. (MLSS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Milestone Scientific Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Samsara Inc. (IOT) Income Statement Analysis – Financial Results
- Shyam Telecom Limited (SHYAMTEL.NS) Income Statement Analysis – Financial Results
- New Providence Acquisition Corp. II (NPABW) Income Statement Analysis – Financial Results
- Yunnan Tourism Co., Ltd. (002059.SZ) Income Statement Analysis – Financial Results
- Duckyang Ind. Co., Ltd. (024900.KS) Income Statement Analysis – Financial Results
Milestone Scientific Inc. (MLSS)
Industry: Medical - Instruments & Supplies
Sector: Healthcare
Website: https://www.milestonescientific.com
About Milestone Scientific Inc.
Milestone Scientific Inc. designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. The company also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, it provides CompuFlo Epidural, a computer controlled anesthesia system for use in various medical applications. Further, the company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Livingston, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.83M | 8.81M | 10.30M | 5.44M | 8.37M | 9.62M | 11.28M | 10.48M | 9.49M | 10.33M | 10.01M | 8.65M | 8.38M | 9.75M | 8.55M | 6.62M | 6.39M | 5.84M | 6.43M | 4.75M | 3.97M | 4.07M | 4.09M | 5.67M | 2.86M | 8.80M | 2.90M | 300.00K |
| Cost of Revenue | 3.03M | 3.91M | 3.99M | 1.82M | 2.66M | 5.19M | 4.31M | 4.18M | 3.05M | 3.63M | 3.20M | 3.06M | 3.02M | 3.53M | 3.46M | 2.68M | 2.90M | 3.04M | 2.52M | 2.42M | 2.00M | 1.98M | 1.97M | 2.91M | 839.46K | 9.60M | 1.60M | 0.00 |
| Gross Profit | 6.79M | 4.90M | 6.31M | 3.62M | 5.72M | 4.43M | 6.97M | 6.31M | 6.44M | 6.70M | 6.81M | 5.59M | 5.36M | 6.22M | 5.09M | 3.94M | 3.49M | 2.81M | 3.91M | 2.34M | 1.97M | 2.09M | 2.12M | 2.77M | 2.02M | -800.00K | 1.30M | 300.00K |
| Gross Profit Ratio | 69.12% | 55.65% | 61.25% | 66.60% | 68.28% | 46.05% | 61.77% | 60.16% | 67.88% | 64.86% | 68.05% | 64.66% | 63.99% | 63.78% | 59.55% | 59.52% | 54.65% | 48.06% | 60.81% | 49.15% | 49.56% | 51.38% | 51.80% | 48.75% | 70.60% | -9.09% | 44.83% | 100.00% |
| Research & Development | 701.38K | 1.15M | 878.21K | 307.85K | 189.92K | 245.64K | 272.75K | 1.27M | 100.86K | 88.24K | 191.35K | 181.98K | 140.05K | 270.49K | 241.32K | 168.52K | 397.35K | 1.01M | 286.26K | 187.99K | 131.02K | 147.71K | 49.94K | 386.25K | 455.33K | 400.00K | 1.00M | 200.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.65M | 11.93M | 11.55M | 9.40M | 7.40M | 5.53M | 5.93M | 6.45M | 6.65M | 6.95M | 5.50M | 6.34M | 5.33M | 6.79M | 5.16M | 3.57M | 3.59M | 5.27M | 8.50M | 7.01M | 9.30M | 7.70M | 2.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 51.41K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.14M | 12.51M | 12.74M | 10.77M | 9.53M | 10.65M | 11.93M | 11.55M | 9.40M | 7.40M | 5.53M | 5.93M | 6.45M | 6.65M | 6.95M | 5.50M | 6.34M | 5.33M | 6.79M | 5.16M | 3.57M | 3.59M | 5.27M | 8.50M | 7.01M | 9.30M | 7.70M | 2.20M |
| Other Expenses | 61.91K | 63.76K | 73.84K | -24.79K | -10.41K | -7.23K | -4.93K | -5.09K | -5.35K | 0.00 | 17.54K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 26.07K | 0.00 | 718.62K | 732.86K | 500.00K | 300.00K | 200.00K |
| Operating Expenses | 13.90M | 13.73M | 13.69M | 11.07M | 9.72M | 10.89M | 12.20M | 12.82M | 9.50M | 7.49M | 5.73M | 6.11M | 6.59M | 6.92M | 7.19M | 5.67M | 6.73M | 6.33M | 7.08M | 5.34M | 3.70M | 3.76M | 5.32M | 9.60M | 8.20M | 10.20M | 9.00M | 2.60M |
| Cost & Expenses | 16.93M | 17.63M | 17.68M | 12.89M | 12.37M | 16.08M | 16.52M | 17.00M | 12.55M | 11.12M | 8.92M | 9.17M | 9.60M | 10.45M | 10.65M | 8.35M | 9.63M | 9.37M | 9.60M | 7.76M | 5.70M | 5.74M | 7.29M | 12.51M | 9.04M | 19.80M | 10.60M | 2.60M |
| Interest Income | 0.00 | 54.61K | 16.36K | 6.71K | 1.54K | 7.45K | 9.30K | 1.29K | 3.84K | 5.06K | 115.00 | 34.00 | 35.00 | 587.00 | 3.15K | 9.02K | 0.00 | 87.41K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 54.61K | 16.36K | 18.08K | 0.00 | 0.00 | 0.00 | 1.29K | 0.00 | 2.67K | 70.80K | 178.97K | 131.84K | 95.14K | 154.03K | 116.37K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 150.77K | 144.38K | 128.93K | 130.28K | 256.47K | 881.29K | 573.15K | 163.37K | 97.38K | 95.84K | 96.12K | 95.13K | 105.39K | 128.64K | 126.39K | 127.24K | 148.91K | 118.76K | 118.15K | 101.92K | 335.22K | 417.99K | 435.18K | 718.62K | 732.86K | 500.00K | 300.00K | 200.00K |
| EBITDA | -6.96M | -8.68M | -7.30M | -7.36M | -3.90M | -5.58M | -4.66M | -6.35M | -2.96M | -694.34K | 1.18M | -596.20K | -1.24M | -572.20K | -2.10M | -1.73M | -3.24M | -3.52M | -3.13M | -2.91M | -1.40M | -1.25M | -2.77M | -6.12M | -5.45M | -10.50M | -7.20M | -2.10M |
| EBITDA Ratio | -70.78% | -98.61% | -70.89% | -135.31% | -1.28% | -41.97% | -41.32% | -60.59% | -31.18% | -15.48% | 2.68% | -6.89% | -11.83% | -7.72% | -22.50% | -33.97% | -53.23% | -63.09% | -62.63% | -61.17% | -35.17% | -32.04% | -69.12% | -103.48% | -162.54% | -123.86% | -262.07% | -766.67% |
| Operating Income | -7.11M | -8.83M | -7.38M | -7.45M | -4.00M | -8.00M | -5.23M | -6.51M | -3.06M | -790.18K | 1.09M | -520.35K | -1.22M | -700.84K | -2.10M | -1.73M | -3.24M | -3.52M | -3.25M | -3.01M | -1.73M | -1.67M | -3.20M | -6.84M | -6.18M | -11.00M | -7.70M | -2.30M |
| Operating Income Ratio | -72.31% | -100.24% | -71.60% | -137.08% | -47.75% | -83.14% | -46.40% | -62.14% | -32.20% | -7.65% | 10.85% | -6.02% | -14.60% | -7.19% | -24.61% | -26.10% | -50.70% | -60.28% | -50.47% | -63.31% | -43.61% | -40.98% | -78.18% | -120.48% | -216.49% | -125.00% | -265.52% | -766.67% |
| Total Other Income/Expenses | 125.53K | 54.61K | 259.82K | -18.08K | -3.64M | 215.00 | 4.37K | -3.80K | -1.51K | -907.81K | 378.23K | -349.95K | -258.50K | 86.33K | 573.43K | 541.13K | 301.55K | 370.52K | 492.87K | 11.34K | 0.00 | 53.93K | 64.49K | -246.28K | -807.60K | 400.00K | 0.00 | 200.00K |
| Income Before Tax | -6.98M | -8.77M | -7.12M | -7.47M | -7.64M | -8.00M | -5.23M | -6.52M | -3.06M | -1.70M | 1.46M | -870.31K | -1.35M | -519.96K | -2.16M | -1.08M | -2.94M | -3.15M | -2.27M | 0.00 | 0.00 | -1.62M | -3.14M | -7.08M | -6.99M | -10.60M | -7.50M | -2.10M |
| Income Before Tax Ratio | -71.04% | -99.62% | -69.08% | -137.41% | -91.27% | -83.13% | -46.36% | -62.18% | -32.22% | -16.43% | 14.63% | -10.06% | -16.12% | -5.33% | -25.23% | -16.31% | -45.98% | -53.94% | -35.26% | 0.00% | 0.00% | -39.66% | -76.60% | -124.82% | -244.77% | -120.45% | -258.62% | -700.00% |
| Income Tax Expense | 0.00 | -66.74K | 333.00 | 15.50K | 18.13K | 23.99K | 19.09K | -19.10K | 36.16K | 9.51K | -843.94K | 7.95K | 258.50K | -86.33K | -573.43K | -541.13K | -301.55K | -370.52K | -413.94K | -11.34K | 680.86K | 770.64K | 791.16K | 673.22K | 790.58K | -300.00K | -300.00K | -400.00K |
| Net Income | -6.93M | -8.71M | -7.12M | -7.49M | -7.66M | -7.43M | -5.19M | -5.95M | -5.47M | -1.70M | 1.46M | -870.31K | -1.48M | -614.51K | -1.53M | -1.19M | -2.94M | -3.15M | -2.75M | -3.00M | -2.41M | -2.44M | -3.99M | -7.51M | -6.97M | -10.70M | -7.40M | -1.90M |
| Net Income Ratio | -70.51% | -98.87% | -69.09% | -137.69% | -91.49% | -77.24% | -45.97% | -56.73% | -57.60% | -16.47% | 14.63% | -10.06% | -17.69% | -6.30% | -17.90% | -17.93% | -45.98% | -53.94% | -42.81% | -63.08% | -60.75% | -59.90% | -97.51% | -132.35% | -244.17% | -121.59% | -255.17% | -633.33% |
| EPS | -0.10 | -0.12 | -0.10 | -0.12 | -0.17 | -0.21 | -0.16 | -0.22 | -0.26 | -0.08 | 0.09 | -0.05 | -0.10 | -0.04 | -0.11 | -0.09 | -0.24 | -0.27 | -0.25 | -0.33 | -0.52 | -0.59 | -1.07 | -2.15 | -2.40 | -3.66 | -3.63 | -1.29 |
| EPS Diluted | -0.10 | -0.12 | -0.10 | -0.12 | -0.17 | -0.21 | -0.16 | -0.22 | -0.26 | -0.08 | 0.08 | -0.05 | -0.10 | -0.04 | -0.11 | -0.09 | -0.24 | -0.27 | -0.25 | -0.33 | -0.52 | -0.59 | -1.07 | -2.15 | -2.40 | -3.66 | -3.63 | -1.29 |
| Weighted Avg Shares Out | 72.78M | 70.61M | 68.83M | 63.06M | 45.74M | 35.30M | 32.70M | 26.97M | 21.03M | 20.06M | 17.13M | 16.08M | 15.17M | 14.82M | 13.39M | 12.67M | 12.14M | 11.79M | 11.01M | 9.15M | 4.67M | 4.16M | 3.71M | 3.50M | 2.91M | 2.92M | 2.04M | 1.47M |
| Weighted Avg Shares Out (Dil) | 72.78M | 70.61M | 68.83M | 63.06M | 45.74M | 35.30M | 32.70M | 26.97M | 21.43M | 20.06M | 17.48M | 16.08M | 15.17M | 14.82M | 13.39M | 12.67M | 12.14M | 11.79M | 11.01M | 9.15M | 4.67M | 4.16M | 3.71M | 3.50M | 2.91M | 2.92M | 2.04M | 1.47M |
Milestone Scientific says dental office reopenings and sales and marketing efforts boosted revenue in third quarter
Milestone Scientific Inc (NYSE:MLSS) reported a 69% uplift in revenue in its third quarter to end-September compared to last year, as dental offices began opening up again and the group's medical sales and marketing initiatives began to stick. For the...
Milestone Scientific, Inc. (MLSS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Milestone Scientific, Inc. (MLSS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Milestone Scientific to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021
ROSELAND, N.J., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that Arjan Haverhals, Chief Executive Officer and President of Milestone Scientific, will...
Milestone Scientific initiates international expansion for its CompuFlo Epidural Instrument
Milestone Scientific Inc. (NYSE:MLSS), a developer of computerized drug delivery instruments that provide painless and precise injections, said it has added three new international distributors for the CompuFlo Epidural Instrument, including Andau Medical in Canada, Sanolabor DD in Slovenia, and...
Milestone Scientific Announces International Expansion for their CompuFlo® Epidural Instrument
Signs distributors in Canada, Slovenia and United Arab Emirates; expands commercial usage at leading hospital in Germany Signs distributors in Canada, Slovenia and United Arab Emirates; expands commercial usage at leading hospital in Germany
Milestone Scientific to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Wednesday, October 6, 2021
ROSELAND, NJ / ACCESSWIRE / October 5, 2021 / Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that the Company has been invited to present at the Fall...
Milestone Scientific approved to supply its CompuFlo Epidural and CathCheck Verification System disposables across Florida's renowned Memorial Healthcare System
Milestone Scientific Inc told investors that its sales force expansion was paying off, as the company had won approval to supply its CompuFlo Epidural and CathCheck Verification System disposables across Florida's renowned Memorial Healthcare System network of hospitals. The company,...
Milestone Scientific Approved as Vendor to Supply CompuFlo® Epidural/ CathCheck™ Verification System Across Florida's Memorial Heathcare System
ROSELAND, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today reported that Memorial Regional Hospital in Hollywood, Fla., has begun the use of...
Milestone Scientific Inc. (MLSS) CEO Arjan Haverhals on Q2 2021 Results - Earnings Call Transcript
Milestone Scientific Inc. (MLSS) CEO Arjan Haverhals on Q2 2021 Results - Earnings Call Transcript
Milestone Scientific, Inc. (MLSS) Reports Q2 Loss, Tops Revenue Estimates
Milestone Scientific, Inc. (MLSS) delivered earnings and revenue surprises of -100.00% and 7.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Source: https://incomestatements.info
Category: Stock Reports